News

Pulmonary Thromboendarterectomy Should Be Considered for PH Before Transplant, Case Report Contends

Chronic thromboembolic pulmonary hypertension (CTEPH) may be mitigated by pulmonary thromboendarterectomy, which prevents the need for lung transplant, a new case report shows. The study, “Pulmonary Thromboendarterectomy for Pulmonary Hypertension Before Considering Transplant,” appeared in The Ochsner Journal. CTEPH is observed in approximately 4% of cases…

Patients with Hyperthyroidism May Develop Mild Pulmonary Hypertension, Study Finds

A significant proportion of patients with hyperthyroidism may have mild pulmonary hypertension (PH), according to the results of a recent study. Increased pulmonary vascular resistance may be the underlying cause of this association. The study, “Relationship Among Pulmonary Hypertension, Autoimmunity, Thyroid Hormones And Dyspnea In Patients With Hyperthyroidism,” was…

Therapies for Chronic Myeloid Leukemia May Trigger PH Onset

Pulmonary hypertension (PH) may be triggered by therapies used in chronic myeloid leukemia (CML) treatment, namely the drugs Gleevec (imatinib), Tasigna (nilotinib), or Sprycel (dasatinib), according to a recent study. The study, titled “Comparative Analysis Of Pulmonary Hypertension In Patients Treated With Imatinib, Nilotinib And Dasatinib,” was published in the…

Study Proves OCT Imaging Technique Useful for Managing PAH in Systemic Sclerosis Patients

An imaging technique called optical coherence tomography (OCT) can effectively determine abnormalities in the lung vasculature of pulmonary arterial hypertension (PAH) patients with systemic sclerosis (SSc), a study shows. The study, “Optical coherence tomography evaluation of pulmonary arterial vasculopathy in Systemic Sclerosis,” appeared in the journal Scientific…

Revatio as Inhaled PAH Treatment Is More Effective Than Tablets Now Available, Study Says

Inhaled Revatio (sildenafil) appears to be superior to current oral forms of this approved pulmonary arterial hypertension (PAH) treatment by allowing for lower doses and potentially fewer systematic side effects, researchers report. They also recommend that a nebulized form of Revatio be produced and moved into clinical testing in patients. The study reporting this finding, “Inhaled Sildenafil As An…

Mifcare Receives Support from HTaPFrance, Inserm to Develop New PAH Therapies

Paris-based biotechnology company Mifcare is getting support from the French pulmonary hypertension patients’ association HTaPFrance for the development of new anti-inflammatory therapies for pulmonary arterial hypertension (PAH). Melanie Gallant-Dewavrin, director of HTaPFrance, said promoting research to fight PAH is one of her association’s goals, “which is why I do not hesitate to…